|
| Monday, January 26, 2026 |
|
|
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. more info >> |
|
|
エーザイとバイオジェン、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」について、早期アルツハイマー病に対する初期療法からの投与を可能とする生物製剤承認一部変更申請が米国 FDA に受理され、優先審査に指定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、抗 Aβプロトフィブリル抗体レカネマブ（一般名）の皮下注オートインジェクター製剤（SC-AI）「LEQEMBI IQLIK」（レケンビ アイクリック）について、週 1 回投与による初期療法に関する生物製剤承認一部変更申請（sBLA）が米国食品医薬品局（FDA）に受理されたことをお知らせします。 more info >> |
|
| Wednesday, January 21, 2026 |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Tuesday, January 13, 2026 |
|
|
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan |
| Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan. more info >> |
|
| Tuesday, January 6, 2026 |
|
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
|
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of LEQEMBI(R) (generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, has been accepted by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Thursday, December 11, 2025 |
|
|
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year |
| Eisai Co., Ltd. has announced that it has been selected for the highest-rated "A" List in the fields of Climate Change and Water Security for 2025 by the global environmental non-profit organization CDP.(1) more info >> |
|
| Tuesday, December 9, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List |
| The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China. more info >> |
|
| Thursday, December 11, 2025 |
|
|
エーザイ、CDP より「気候変動」「水セキュリティ」分野で最高評価 A リストに 2 年連続でダブル選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、国際的な環境非営利団体 CDP1より 2025 年の「気候変動」および「水セキュリティ」分野において、最高評価である A リストに選定されましたのでお知らせします。2 年連続での両分野における A リストへのダブル選定となります。 more info >> |
|
| Thursday, December 4, 2025 |
|
|
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI(R)) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. more info >> |
|
| Wednesday, December 3, 2025 |
|
|
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest data confirming the pharmacological effect of lecanemab, an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. more info >> |
|
|
|
|
